The estimated Net Worth of Jeffrey J Kraws is at least $438 mil dollars as of 3 August 2020. Mr. Kraws owns over 10,000 units of Theriva Biologics Inc stock worth over $136,006 and over the last 13 years he sold SYN stock worth over $90,460. In addition, he makes $212,000 as Non-Executive Independent Chairman of the Board at Theriva Biologics Inc.
Sign up
Mr. Kraws SYN stock SEC Form 4 insiders trading
Jeffrey has made over 5 trades of the Theriva Biologics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of SYN stock worth $3,500 on 3 August 2020.
The largest trade he's ever made was exercising 228,773 units of Theriva Biologics Inc stock on 14 March 2017 worth over $20,590. On average, Jeffrey trades about 15,485 units every 69 days since 2012. As of 3 August 2020 he still owns at least 133,339 units of Theriva Biologics Inc stock.
You can see the complete history of Mr. Kraws stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeffrey Kraws biography
Jeffrey J. Kraws serves as Non-Executive Independent Chairman of the Board of the Company. Mr. Kraws has been a member of the Company’s Board of Directors since January of 2006, and was appointed independent, non-executive Chairman of the Board in May 2012. Since 2003, Mr. Kraws has served as Chief Executive Officer and co-founder of Crystal Research Associates and CRA Advisors, and since February 2012, he has served as partner and co-founder of TopHat Capital, LLC. Mr. Kraws has served as the Co-President of Ra Medical Systems Inc. (NYSE RMED), a medical device company, since May 2018 and as President from August 2016 until May 2018. Mr. Kraws is a partner at Grannus Securities Pty Ltd. (an Australian based private equity fund) since November 2015. Well-known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry. Among other awards, he was given a “5-Star Rating” in 2001 by Zacks and was ranked the number one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior to founding Crystal Research Associates, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck & Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Company). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown & Sons, and Buckingham Research.
What is the salary of Jeffrey Kraws?
As the Non-Executive Independent Chairman of the Board of Theriva Biologics Inc, the total compensation of Jeffrey Kraws at Theriva Biologics Inc is $212,000. There are 2 executives at Theriva Biologics Inc getting paid more, with Steven Shallcross having the highest compensation of $1,108,610.
How old is Jeffrey Kraws?
Jeffrey Kraws is 56, he's been the Non-Executive Independent Chairman of the Board of Theriva Biologics Inc since 2012. There are 4 older and no younger executives at Theriva Biologics Inc. The oldest executive at Theriva Biologics Inc is John Monahan, 73, who is the Director.
What's Jeffrey Kraws's mailing address?
Jeffrey's mailing address filed with the SEC is C/O SYNTHETIC BIOLOGICS, INC.,, 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MD, 20850.
Insiders trading at Theriva Biologics Inc
Over the last 13 years, insiders at Theriva Biologics Inc have traded over $8,016,723 worth of Theriva Biologics Inc stock and bought 6,682,900 units worth $10,572,593 . The most active insiders traders include Randal Jintrexon Corp Kirk, Steve H Kanzer y Scott Tarriff. On average, Theriva Biologics Inc executives and independent directors trade stock every 223 days with the average trade being worth of $899,000. The most recent stock trade was executed by Steven A Shallcross on 10 May 2021, trading 50,000 units of SYN stock currently worth $24,500.
What does Theriva Biologics Inc do?
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
What does Theriva Biologics Inc's logo look like?
Complete history of Mr. Kraws stock trades at Theriva Biologics Inc y Catheter Precision
Theriva Biologics Inc executives and stock owners
Theriva Biologics Inc executives and other stock owners filed with the SEC include:
-
Steven Shallcross,
Chief Executive Officer, Chief Financial Officer, Director -
Steven A. Shallcross CPA,
CEO, CFO, Treasurer, Corp. Sec. & Director -
Jeffrey Kraws,
Non-Executive Independent Chairman of the Board -
John Monahan,
Director -
Jeffrey Wolf,
Independent Director -
Dr. Frank Tufaro Ph.D.,
Chief Operating Officer -
Lara M. Guzman,
Sr. Director of Project Operations -
Dr. Michael Kaleko,
Sr. VP of R&D -
Dr. Vince Wacher,
Head of Product and Corp. Devel. -
Vincent I. Perrone,
Director of Corp. Communication -
Jeffrey Scott Riley,
CEO and President -
Randal Jintrexon Corp Kirk,
-
Joseph A. Sliman,
Chief Medical Officer -
Steve H Kanzer,
10% owner -
Charles Evan Ballantyne,
Chief Financial Officer -
Scott Tarriff,